Fuller & Thaler Asset Management
NBIX icon

Fuller & Thaler Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Fuller & Thaler Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.2M Buy
179,149
+91,799
+105% +$13.6M 0.08% 267
2026
Q1 		$11.5M Buy
+87,350
New +$11.6M 0.04% 300

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fuller & Thaler Asset Management's NBIX Position: Q2 2026 in Review

Fuller & Thaler Asset Management increased its Neurocrine Biosciences (NBIX) stake by 105% in Q2 2026, buying an estimated $13.6M and bringing the position to 179,149 shares worth $30.2M. The position accounts for 0.08% of the portfolio, ranked #267.

Fuller & Thaler Asset Management first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fuller & Thaler Asset Management held 179,149 shares of Neurocrine Biosciences worth $30.2M as of Q2 2026.
  • Fuller & Thaler Asset Management bought 91,799 Neurocrine Biosciences shares in Q2 2026, an estimated $13.6M.
  • Neurocrine Biosciences made up 0.08% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #267 holding.
  • Fuller & Thaler Asset Management first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.